

Case Number:	CM13-0022806		
Date Assigned:	11/15/2013	Date of Injury:	09/14/2007
Decision Date:	02/04/2014	UR Denial Date:	08/26/2013
Priority:	Standard	Application Received:	09/11/2013

HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to a physician reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. The physician reviewer is Board Certified in Anesthesiologist has a subspecialty in Pain Management and is licensed to practice in California. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The physician reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/services. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

The patient reported a work-related injury on 09/14/2007. There was no clinical documentation submitted with this request. A request was made for 1 prescription of Fexmid 7.5 mg #60.

IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

1 prescription of Fexmid: Upheld

Claims Administrator guideline: Decision based on MTUS Chronic Pain Treatment Guidelines.

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Cyclobenzaprine Page(s): 41-42.

Decision rationale: California Chronic Pain Medical Treatment Guidelines indicate that cyclobenzaprine is recommended for a short course of therapy and is not recommended to be used for longer than 2 to 3 weeks. There was no documentation submitted noting how long the patient has been taking the medication Fexmid. Guidelines state that cyclobenzaprine is more effective than placebo in the management of back pain, although the effect is modest and comes at the price of adverse effects. Furthermore, the addition of cyclobenzaprine to other agents is not recommended. There was no physical exam noted for the patient and a list of the patient's

current medications was not submitted. Given the above, the decision for 1 prescription of Fexmid 7.5 mg #60 is non-certified.